In June 2007 Shire announced that it has received an approval letter from the U.S. Food and Drug Administration (FDA) for Intuniv extended release tablets. Intuniv will be used for the treatment of ADHD. It is a nonstimulant and is not a controlled substance. According to ShireNews, Matthew Emmens, CEO of Shire, said "when approved, Intuniv will be the first medication indicated to treat ADHD symptoms by selectively targeting alpha-2A-receptors in the prefrontal cortex, an area of the brain that is thought to manage executive functioning tasks." The medication is indicated for use in children between the ages of 6 - 17. It will be available in dosage strengths of 1 mg to 4 mg daily.
Oct 18, 2007
Intuniv....the latest ADHD medication
In June 2007 Shire announced that it has received an approval letter from the U.S. Food and Drug Administration (FDA) for Intuniv extended release tablets. Intuniv will be used for the treatment of ADHD. It is a nonstimulant and is not a controlled substance. According to ShireNews, Matthew Emmens, CEO of Shire, said "when approved, Intuniv will be the first medication indicated to treat ADHD symptoms by selectively targeting alpha-2A-receptors in the prefrontal cortex, an area of the brain that is thought to manage executive functioning tasks." The medication is indicated for use in children between the ages of 6 - 17. It will be available in dosage strengths of 1 mg to 4 mg daily.
Subscribe to:
Post Comments (Atom)
I would absolutely love to be able to get a prescription for a NON-controlled substance. However, "new" medications scare me. Actually, all medications scare me, but new ones scare me even more. Maybe after it's been out for a while.
ReplyDeleteThanks for stopping by my blog. I'm trying to keep up with it, but I'm not doing so well. Where do you find the energy?
Intuniv is an extended release version of Tenex (guanfacine), already prescribed off-label for ADHD, to my understanding. The only 'new' part is that it is ER, and officially FDA approved, rather than off-label prescribing.
ReplyDeleteAnyone tried it yet?